MODD

Business Context and Reporting Period

Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2025
Business Overview: Modular Medical is a pre-revenue medical device company developing innovative insulin pumps. The company received FDA 510(k) clearance in September 2024 for its initial product, the MODD1, a two-part patch pump designed to simplify insulin delivery for Type 1 and Type 2 diabetes patients. The company plans to commence initial shipments in the quarter ending September 30, 2025. It is also developing a successor product, "Pivot," a tubeless version, with FDA submission expected by October 31, 2025.

Key Financial Metrics

Note: Financial figures are in thousands unless otherwise noted. The company has no debt obligations listed in the balance sheet liabilities, consisting primarily of lease liabilities and accounts payable.

Material Changes vs. Prior Period

• Regulatory Milestone: The most significant development was the receipt of FDA 510(k) clearance for the MODD1 pump in September 2024, enabling commercialization.
• Capital Raising: The company raised substantial capital in Fiscal 2025, including a private placement in March 2025 (net proceeds ~$11.4 million) and a public offering in November 2024 (net proceeds ~$7.3 million), compared to a registered direct offering in Fiscal 2024.
• Expense Growth: Research and Development (R&D) expenses increased by 14.1% to $14.7 million, driven by increased personnel costs, depreciation, and travel. General and Administrative (G&A) expenses decreased by 6.4% to $4.4 million due to reduced stock-based compensation and marketing costs.
• Loss Expansion: Net loss increased by approximately $1.3 million year-over-year, reflecting continued investment in product development and commercialization preparation.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Commercialization: Initial shipments of the MODD1 are targeted for the quarter ending September 30, 2025.
• Product Roadmap: Submission of the 510(k) for the "Pivot" (tubeless) product is expected by October 31, 2025, with clearance anticipated by March 31, 2026. CE mark clearance for European markets is expected in Q1 2026.
• Manufacturing: The company is transitioning manufacturing to a tier-one partner, Phillips Medisize, to scale production.

Risks and Contingencies:

• Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern for 12 months from the report date. Cash on hand ($13.1 million) is deemed insufficient to fund operations without additional financing.
• Reimbursement: The MODD1 currently lacks insurance coverage and reimbursement approval. Commercial success is heavily dependent on securing third-party payor coverage.
• Competition: The market is dominated by Medtronic, Tandem, and Insulet. Modular Medical must compete on cost, simplicity, and usability.
• Regulatory: Future products (Pivot) require new regulatory clearances, which are not guaranteed.

Investor Verification Checklist

• Liquidity Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" going concern warning and the $13.1 million cash balance.
• Reimbursement Strategy: Confirm progress on insurance coverage negotiations with major payors, as the product is currently not reimbursed.
• Manufacturing Scale-up: Monitor the validation status with Phillips Medisize and the ability to meet initial shipment targets for Q3 2025.
• Pivot Timeline: Track the submission date for the Pivot product (targeted Oct 2025) and any potential delays in FDA clearance.
• Dilution Risk: Assess the impact of future equity financings on existing shareholders, given the company's pre-revenue status and high cash burn.